Job title: Director, Head of Analytics, Cell Therapy
Chelsea is currently Head of Analytical Development for Cell Therapies in Takeda. She oversees analytical strategies across Cell Therapy pipelines and leads a team who develop integrated analytical capabilities to enable product quality control, drive product understanding and next-generation design. In her previous role at Novartis, Chelsea contributed significantly on product analytics and CQA discovery for CTL019 which was later approved for ALL as Kymriah. She later led a group focused on clinical biomarker development in Novartis. Chelsea received her Ph.D from Texas A&M Health Science Center and competed postdoc training in Yale University.